<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669445</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/18/0212</org_study_id>
    <nct_id>NCT03669445</nct_id>
  </id_info>
  <brief_title>Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma</brief_title>
  <acronym>IFM2018-01</acronym>
  <official_title>Toward a Risk-adapted Strategy to Cure Myeloma : An Intensive Program With Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Standard Risk Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant : a Phase II Study of the Intergroupe Francophone du Myélome (IFM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the minimal residual disease-negativity rate
      after administration of the combination of Lenalidomide, Ixazomib, Dexamethasone and
      Daratumumab as induction and consolidation therapy in an intensive program in newly diagnosed
      standard risk multiple myeloma patients.

      For the induction therapy, each patient received 6 cycles of Lenalidomide, Ixazomib,
      Dexamethasone and Daratumumab, then peripheral blood stem cell harvest, intensification with
      autologous stem cell transplantation, consolidation therapy and maintenance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, multicenter, non-randomized, open-label study to evaluate the safety and
      efficacy of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in patients with newly
      diagnosed multiple myeloma.

      The patient population will consist of adult men and women ≤ 65 years, who have a confirmed
      diagnosis of standard risk multiple myeloma, who meet eligibility criteria.

      Treatment periods will be defined as 21-day cycles for induction, and 28-day cycles for
      consolidation, and maintenance. Patients will be seen at regular treatment cycle intervals
      while they are participating in the study.

      Patients will be assessed for disease response and progression according to the International
      Myeloma Working Group criteria at each cycle during induction and consolidation and every
      other cycle during maintenance.

      Eastern Cooperative Oncology Group performance status, adverse events, laboratory values, and
      vital sign measurements will be collected and assessed to evaluate the safety of therapy
      throughout the study.

      Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria
      for Adverse Events. Patients will attend an End of Treatment visit after receiving their last
      dose of study drug and will continue to be followed for other follow-up assessments specified
      in the Schedule of events.

      All patients will be followed for survival after progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>minimal residual disease-negativity rate</measure>
    <time_frame>22 months</time_frame>
    <description>after completion of the consolidation therapy and before maintenance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 54 Months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>3 months, 5 months, 7 months, 13 months, 25 months</time_frame>
    <description>Response rates according to the IMWG criteria after induction, high dose Melphalan, consolidation and maintenance therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>four drugs combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>21-day cycles induction and 28-day cycles consolidation</description>
    <arm_group_label>four drugs combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy</description>
    <arm_group_label>four drugs combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>21-day cycles induction and 28-day cycles consolidation</description>
    <arm_group_label>four drugs combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>21-day cycles induction and 28-day cycles consolidation</description>
    <arm_group_label>four drugs combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo symptomatic myeloma on the International Myeloma Working Group Diagnostic
             Criteria for the Diagnosis of Multiple Myeloma

          -  Measurable disease requiring systemic therapy defined by serum M-component ≥ 10g/l or
             urine M-component ≥ 200 mg/24h or involved free light level ≥ 100 mg/l

          -  Eastern Cooperative Oncology Group performance status 0, 1 or 2

          -  Eligible to high dose therapy

        Exclusion Criteria:

          -  Previously treated with any systemic therapy for multiple myeloma

          -  Clinical signs of central nervous system involvement

          -  Renal insufficiency defined as estimated Glomerular Filtration Rate lower or equal to
             40 ml/min/1.73 m2

          -  Hepatic impairment defined as aspartate transminase or alanine transaminase greater or
             equal to 3 x upper limit of normal, or Total bilirubin greater or equal to 3 x upper
             limit of normal

          -  Platelet count &lt; 75,000 per µL

          -  Absolute neutrophil count ≤ 1,000 cells/mm3

          -  Evidence of current uncontrolled cardiovascular conditions

          -  Female patients who are both lactating and breastfeeding or have a positive serum
             pregnancy test during the screening

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before first dose of study drug

          -  Grade 3 or higher peripheral neuropathy, or grade 2 with pain, on clinical examination
             during the screening period

          -  Known or suspected chronic obstructive pulmonary disease with a Forced Expiratory
             Volume in 1 second &lt; 50% of predicted normal

          -  Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin,
             carbamazepine, phenytoin, phenobarbital), or use of St. John's wort within 14 days
             before initiation of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel ATTAL, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura BOGDANOVITCH, CRA</last_name>
    <phone>05 61 77 84 37</phone>
    <phone_ext>+33</phone_ext>
    <email>laura.bogdanovitch@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyrille HULIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret MACRO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis CAILLOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara MARIETTE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry FACON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel KARLIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie STOPPA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurore PERROT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MOREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine ESCOFFRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hosptial Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Attal, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lotfi BENBOUBKER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly Diagnosed Multiple myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Ixazomib</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

